Sowa-Kućma Magdalena, Pańczyszyn-Trzewik Patrycja, Jaeschke Rafał R
Department of Human Physiology, Institute of Medical Sciences, Medical College of Rzeszów University, Kopisto 2a, 35-315 Rzeszów, Poland.
Centre for Innovative Research in Medical and Natural Sciences, Medical College of Rzeszów University, Warzywna 1a, 35-310 Rzeszów, Poland.
Int J Mol Sci. 2024 Dec 11;25(24):13289. doi: 10.3390/ijms252413289.
Lumateperone is a novel antipsychotic recently approved for the treatment of schizophrenia. Its unique pharmacological profile includes modulation of serotonergic, dopaminergic, and glutamatergic neurotransmission, differentiating it from other second-generation antipsychotics. This paper explores the pharmacological features and clinical potential of lumateperone across neuropsychiatric conditions. A review of current literature, including pharmacokinetic and pharmacodynamic studies, was conducted. It focused on lumateperone's mechanism of action and receptor-binding profile, and clinical trials assessing its efficacy and safety in schizophrenia and other psychiatric disorders. Lumateperone demonstrates high affinity for 5-HT receptors, moderate affinity for D receptors, and low affinity for H and 5-HT receptors. It acts as a presynaptic D agonist and a postsynaptic antagonist, contributing to a favorable side-effect profile with reduced extrapyramidal symptoms. Clinical trials suggest that lumateperone is effective in reducing both positive and negative symptoms of schizophrenia, with minimal metabolic and cardiovascular risks. It is also being explored as an adjunctive therapy for major depressive disorder and bipolar depression. Lumateperone presents a promising therapeutic option for schizophrenia with a novel mechanism of action and a favorable safety profile. Its potential application in other psychiatric conditions warrants further investigation, particularly in treatment-resistant populations.
鲁马西酮是一种最近被批准用于治疗精神分裂症的新型抗精神病药物。其独特的药理学特性包括对5-羟色胺能、多巴胺能和谷氨酸能神经传递的调节，这使其有别于其他第二代抗精神病药物。本文探讨了鲁马西酮在各种神经精神疾病中的药理学特征和临床潜力。对当前文献进行了综述，包括药代动力学和药效学研究。重点关注鲁马西酮的作用机制和受体结合情况，以及评估其在精神分裂症和其他精神疾病中的疗效和安全性的临床试验。鲁马西酮对5-羟色胺受体具有高亲和力，对多巴胺受体具有中等亲和力，对组胺和5-羟色胺受体具有低亲和力。它作为一种突触前多巴胺激动剂和突触后拮抗剂，有助于产生有利的副作用特征，减少锥体外系症状。临床试验表明，鲁马西酮在减轻精神分裂症的阳性和阴性症状方面有效，代谢和心血管风险最小。它也正在被探索作为重度抑郁症和双相抑郁症的辅助治疗方法。鲁马西酮以其新颖的作用机制和良好的安全性，为精神分裂症提供了一种有前景的治疗选择。其在其他精神疾病中的潜在应用值得进一步研究，特别是在难治性人群中。
